Current and ongoing progress in the therapy for resectable esophageal cancer

Charles R. Thomas

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalDiseases of the Esophagus
Issue number4
StatePublished - Sep 2005
Externally publishedYes


  • Esophageal cancer

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Current and ongoing progress in the therapy for resectable esophageal cancer'. Together they form a unique fingerprint.

Cite this